MDedge Hematology and Oncology

MDedge Hematology & Oncology provides crucial, up-to-date, evidence-driven information that is essential for hematologist-oncologists and medical oncologists. Its user-friendly and interactive formats allow busy professionals to easily stay informed and gain insights necessary for delivering high-quality care that enhances patient outcomes.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#80128

United States

#24476

Health/Health

#584

Traffic sources

Monthly visitors

Articles

What Hematologists Should Know About Cutaneous Porphyria and Hemochromatosis

1 week ago | mdedge.com | Randy Dotinga

One patient, a 39-year-old woman, went to a dermatologist seeking care for fluid-filled blisters over the backs of her hands and arms. Another patient, a 56-year-old man, sought care from his general practitioner owing to fatigue. Their presentations were quite different, but the two patients shared one thing in common: iron overload. Both ended up in the care of hematologists who diagnosed their conditions as porphyria cutanea tarda (PCT) and hemochromatosis, respectively.
How Doctors Use Travel to Heal Themselves

2 weeks ago | mdedge.com | Dina Cheney

Whatever’s ailing you, a vacation might just be the cure. Yes, getting away can improve your health, according to research published in in 2023. It might help combat symptoms of aging, suggested a 2024 study in Journal of Travel Research. But it could also have even more powerful psychological and physical benefits, transforming your life before you pack a bag and long after you return home. This news organization spoke with two healthcare professionals who believe in the healing power of travel.
Assay Shows Promise for Early-Stage Melanoma Risk Assessment Beyond SNLB

2 weeks ago | mdedge.com | Sharon Worcester

FROM WCM-EADO 2025A noninvasive clinicopathologic and gene expression profiling (CP-GEP)–based tool, the Merlin assay, shows promise for identifying recurrence risks in patients with early-stage melanoma who do not undergo sentinel lymph node biopsy (SNLB).
FDA Approves Pluvicto for Earlier Use in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

3 weeks ago | mdedge.com | Sharon Worcester

Consent Legitimate InterestAlways ActiveThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
The Physician Associate Advantage: A Vital Solution for Better Patient Care

3 weeks ago | mdedge.com | Kayt Sukel

Late last year, the Health Resources and Services Administration projected a shortage of nearly 190,000 physicians across specialties by 2037. They noted, however, that we could mitigate the lack of doctors in some specialties by increasing the use of physician associates (PAs), especially with new and pending legislation expanding PAs’ scope of practice.
A Better Biopsy for Prostate Cancer?

3 weeks ago | mdedge.com | Howard Wolinsky

Micro-ultrasound–guided biopsies were found for the first time to be “noninferior” to MRI-guided procedures, according to new research presented at the 2025 annual congress of the European Association of Urology. The OPTIMUM study found 4.5% more clinically significant cancers among men who underwent micro-ultrasound–guided biopsies of the prostate than in those scanned using MRI.
Study Gives Clinical Edge to Transperineal Prostate Biopsies

3 weeks ago | mdedge.com | Howard Wolinsky

In the largest head-to-head randomized trial of its kind, UK researchers found transperineal prostate biopsies using local anesthesia (LATP) superior to the transrectal approach in detecting clinically significant cancers. The TRANSLATE study, with more than 1100 patients, found LATP identified 5.7% more cases of clinically significant prostate cancer, defined as Grade Group 2 or higher, than biopsies using transrectal ultrasonography (TRUS).
FDA OKs Guselkumab for Crohn’s Disease

4 weeks ago | mdedge.com | Megan Brooks

The United States Food and Drug Administration (FDA) approved guselkumab (Tremfya, Johnson & Johnson) for the treatment of adults with moderately to severely active Crohn’s disease (CD). The approval marks the fourth indication for guselkumab, which was approved for moderate to severe plaque psoriasis in 2017, active psoriatic arthritis in 2020, and moderately to severely active ulcerative colitis in 2024.
Intensive Nutrition Therapy Improves Outcomes in Alcohol-Related ACLF

4 weeks ago | mdedge.com | Megan Brooks

FROM CLINICAL GASTROENTEROLOGY AND HEPATOLOGYA recent study supports the importance of intensive nutrition therapy in managing patients with alcohol-related acute-on-chronic liver failure (ACLF). In a randomized controlled trial, compared with standard care, dietitian-supported, intensive nutritional therapy improved survival, reduced frailty, and lowered hospitalization rates in men with alcohol-related ACLF.
VA Shake-up Disrupts Mental Health Services for Some US Veterans

1 month ago | mdedge.com | Robin Respaut

SAN FRANCISCO (Reuters) — Joey Cortez, who served 24 years in the US Air Force, had been waiting since August to see a mental health specialist from the Department of Veterans’ Affairs, when he experienced a fresh jolt of anxiety. Cortez was fired last month from his human resources job at the agency - one of about 2400 employees who lost their jobs at Veterans’ Affairs (VA) in the first wave of President Donald Trump’s efforts to shrink the federal workforce.